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Adamantane is a very common building block in medicinal 
chemistry.1 So far, seven adamantane derivatives have been 
introduced in clinical use for a variety of diseases and molecular 
targets (Figure 1) and hundreds of derivatives have been tested 
against different targets. 
Interestingly, the rapid inspection of the structures of the 
adamantane derivatives shown in Figure 1 reveals as a general 
trend that the polycyclic scaffold is substituted at the C-1 position. 
Of note, the anti-influenza A activity of amantadine is significantly 
higher than that of its isomer, 2-aminoadamantane.2  
 
——— 
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Figure 1. Clinically-approved adamantane derivatives. Amantadine, 
rimantadine and tromantadine are anti-virals, the first two are M2 channel 
blockers and are anti-Influenza drugs, and tromantadine inhibits herpex virus 
simplex replication; memantine is a NMDA receptor antagonist used in the 
treatment of Alzehimer’s disease; adapalene inhibits keratinocyte 
differentiation and proliferation and is used for the treatment of acne; and 
saxagliptin and vildagliptin are DPP-IV inhibitors used to treat type 2 diabetes. 
 
 
In recent years, more than 25 pharmaceutical companies have 
been working on the synthesis of 11-hydroxysteroid 
dehydrogenase type 1 (11-HSD1) inhibitors, as a potential new 
candidates for the treatment of type II diabetes and metabolic 
syndrome.3 On the one hand, contrary to the aforementioned trend 
observed in clinically approved adamantanes, most of the 11-
HSD1 inhibitors evaluated are 2-adamantyl substituted derivatives 
(Figure 2).4,5 However, for these derivatives no comparison 
between the activities of compounds substituted at the C-1 and C-
2 positions is available. On the other hand, a potential advantage 
of positioning the substituent at the 1-position is that one of the 
metabolically labile positions of the adamantane would be 
blocked. Also, for any given substituent, the theoretical clogP 
value of the 1-substituted analog is usually lower than that of the 
2-substituted derivative.6 
The synthesis and pharmacological evaluation of a series of 1-
adamantyl amide 11-HSD1 inhibitors has been previously 
reported by Webster et al.7 Of note, inhibitors 1 and 2 were found 






The adamantane scaffold is found in several marketed drugs and in many investigational 11-
HSD1 inhibitors. Interestingly, all the clinically approved adamantane derivatives are C-1 
substituted. We demonstrate that, in a series of paired adamantane isomers, substitution of the 
adamantane in C-2 is preferred over the substitution at C-1 and is necessary for potency at human 
11-HSD1. Furthermore, the introduction of an oxygen atom in the hydrocarbon scaffold of 
adamantane is deleterious to 11-HSD1 inhibition. Molecular modeling studies provide a basis to 
rationalize these features. 








to be equipotent compounds (Figure 3). Later, Xia et al. reported 
that the C-2 substituted amide 3 was 20 times more potent than its 
1-isomer, 4 (Figure 3).8 
Taking into account these seemingly contradictory results and 
the scarcity of data on 1-substituted adamantane derivatives 
evaluated as 11-HSD1 inhibitors,5 we decided to synthesize a 
small series of 1- and 2-adamantyl derivatives featuring fragments 
of proven inhibitors of 11-HSD1 in order to compare their 
pharmacological behaviour. 
Moreover, considering that very few heteroadamantanes have 
been biologically tested as 11-HSD1 inhibitors,9 we also 
evaluated some 1- and 5-substituted 2-oxaadamantanes. The 
introduction of an oxygen atom in the scaffold increases the polar 
surface area and decreases the overall lipophilicity. Thus, if 
potency is retained, the lipophilic ligand efficiency, which is one 
of the most significant parameters that normalizes potency relative 





Figure 2. Selected adamantyl-based 11-HSD1 inhibitors. 
 
 
Figure 3.Structures of 11-HSD1 inhibitors 1-4. 
 
We started from known urea 5, an 11-HSD1 inhibitor reported 
by Vitae.11 In our microsomal assay, 5 was shown to be a 
submicromolar inhibitor of the human 11-HSD1 enzyme (IC50 = 
0.87 M). Table 1 shows the structures and the percentage of 
inhibition of human 11-HSD1 at 10 M of the novel compounds. 
The IC50 value of the more potent derivatives is also included. 
All the compounds were synthesized in medium to high yields 
using standard chemistry from four known amines: amantadine (1-
aminoadamantane), 2-aminoadamantane, 5-amino-2-
oxaadamantane,12 and 3-methyl-2-oxaadamantane-1-amine13 (see 
details in Supplementary Material). Briefly, the reaction of 
amantadine with 1-piperidinecarbonyl chloride in 
dichloromethane in the presence of triethylamine furnished, after 
column chromatography, urea 6 in 31% yield.14 In the same way, 
starting from the known 3-methyl-2-oxaadamante-1-amine, urea 7 
was obtained in 34% yield. We also synthesized amides 8 and 9 in 
high yields, by reaction of amantadine with 3,5-dichloro-4-
aminobenzoic acid or cyclohexanecarboxylic acid, respectively.15 
Surprisingly, in our microsomal assay ureas 6 and 7 and amide 
8 did not inhibit the human 11-HSD1 enzyme. Under the same 
conditions, amide 9 only inhibited 20% the enzyme activity. 
Oxaadamantanes 10 and 11 were also very poor inhibitors. 
Taking into account the aforementioned results and that the 
corresponding C-2 isomers of 8 and 9 had not been previously 
tested, we synthesized both amides from 2-aminoadamantane. By 
way of contrast with the lack of inhibitory activity of their C-1 
isomers, amides 12 and 13 displayed potent, nanomolar inhibition. 
Also, in agreement with the previous trend observed in going from 
ureas 6 and 7 to their corresponding amides 9 and 10, the novel 
amide 12 was more potent than our previous hit 5. It was 
noteworthy that ring contraction from 12 to 14 led to a less potent 
inhibitor. 
Overall, for the three pairs of isomers evaluated here, 
substitution in position 2 of the adamantyl scaffold consistently 
leads to more potent inhibitory activity of human 11-HSD1. 
The introduction of an oxygen atom in the adamantane does not 
improve the activity within the series of the C-1 substituted 
derivatives. As Ye et al. found, within a series of 2,2-disubstituted 
adamantanes, that the corresponding oxaadamantane analogs 
performed poorly,9b we have not evaluated oxaadamantane 
derivatives with the amino group attached to a methylene group of 
the polycyclic ring.16 
In order to rationalize these results we combined docking 
studies with molecular dynamics simulations to examine the 
structural integrity of the binding of compounds 5, 6, and 12. Let 
us note that the inhibitory activities of 5 and 6, which only differ 
in the substitution at positions C1 and C2, vary from 87% (5) to 
3% (6). On the other hand, compound 12 involves the replacement 
of the piperidine moiety present in 5 by the cyclohexyl one in 12, 
leading to a moderate increase of the inhibitory activity from 87% 
(5) to 100% (12). 
Compounds were docked in the binding cavity of human 11-
HSD1 using Glide.17 In all cases the best scored poses mimicked 
the binding mode of PF-877423 (Figure S1 in Supporting 
Information), which is a potent adamantyl-based inhibitor against 
the human enzyme (Ki = 1.4 nM).
18 Thus, all the compounds 
retained the hydrogen bond formed between the carbonyl oxygen 
of the amide/urea moiety with the hydroxyl group of Ser170 and 
the adamantyl cage filled a common site in the binding pocket.  
 

















































































11-HSD1 inhibition was determined in mixed sex, Human Liver Microsomes 
(Celsis In-vitro Technologies) by measuring the conversion of 3H-cortisone to 
3H-cortisol in a cortisol-Scintillation Proximity Assay. Percentage inhibition 
was determined relative to a no inhibitor control. 
 
 
Figure 4. Last snapshot of a representative molecular dynamics simulation for 
the complexes between human 11-HSD1 and compounds PF-877423 (top 
left), 6 (top right), 12 (bottom left) and 5 (bottom right). In all cases residues 
Tyr183 and Ser170, the NADP cofactor and the ligand are represented as sticks 
and only the polar hydrogens are shown. The shape of the binding cavity is 
shown as a white contour. 
 
Three independent 50 ns MD simulations were run for each 
ligand-receptor complex, and additional runs were performed for 
the complex with PF-877423, which was used as a reference 
system. All the simulations were stable except that of the complex 
with the C1-substituted compound 6, since the ligand was released 
from the binding site in one simulation. Upon exclusion of this 
latter trajectory, the root-mean square deviation (RMSD) profiles 
were similar in all cases. Thus, the RMSD of the protein backbone 
varied from 1.5 to 2.2 Å, whereas the residues in the binding site 
showed a larger RMSD (2.5-3.7 Å) due to the enhanced flexibility 
of the loops that enclose the binding pocket. 
The hydrogen bond formed between the inhibitor and the 
hydroxyl group of Ser170 was retained in all cases (average 
distance of 2.8 Å). Often, an additional hydrogen bond with the 
hydroxyl unit of Tyr183 was transiently formed. Nevertheless, 
compound 6 consistently showed a higher root-mean square 
fluctuation (1.4 Å) compared to inhibitors 5 and 12 (RMSF of 0.8 
Å), suggesting a poorer fit of the hydrophobic cage in the binding 
cavity due to the change in the substitution pattern from position 
C1 in 6 to position C2 in 5 and 12. This reflects the larger steric 
hindrance of the adamantyl cage with the NADP nicotinamide ring 
arising from the C1-substitution, because C2-derived compounds 
are found to adopt a configuration where the C2-H unit is primarily 
oriented toward the nicotinamide ring (Figure 4) 
Finally, the moderate increase in the inhibitory activity of 
compound 12 relative to 5 may be ascribed to the enhanced 
hydrophobicity afforded by the cyclohexane unit, as noted in their 
respective clogP values of 4.5 and 3.6, determined from quantum 
mechanical IEF/MST continuum solvation calculations.19 This 
trend agrees with similar findings reported for series of structurally 
related compounds.20 
In conclusion, bearing in mind the aforementioned 
pharmacological results, it is clear that for potent 11-HSD1 
inhibitory activity, 2-substituted adamantanes are preferred over 
their corresponding 1-substituted counterpart. Also, the 
introduction of an oxygen atom in the polycyclic scaffold did not 
improve the activity (compare 9 vs 10 and 11). 
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